Intra-amniotic Delivery of CFTR-expressing Adenovirus Does Not Reverse Cystic Fibrosis Phenotype in Inbred CFTR-knockout Mice
| Autor: | Suzanne M. K. Buckley, Alan W. Cuthbert, S Jezzard, Simon N. Waddington, A Bergau, William H. Colledge, L J MacVinish, Charles Coutelle, Michael Themis |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Amniotic fluid
Cystic Fibrosis Genetic enhancement Cystic Fibrosis Transmembrane Conductance Regulator Biology medicine.disease_cause Cystic fibrosis Adenoviridae Mice Gene therapy Pregnancy Drug Discovery CF transmembrane conductance regulator medicine Genetics Animals Humans Adenovirus Molecular Biology Mice Knockout Regulation of gene expression Pharmacology Reproducibility of Results Genetic Therapy Amniotic Fluid medicine.disease Phenotype Cystic fibrosis transmembrane conductance regulator Mice Inbred C57BL ComputingMilieux_GENERAL Gene Expression Regulation Immunology Knockout mouse biology.protein Pregnancy Animal Molecular Medicine Female |
| Zdroj: | Molecular Therapy. 16(5):819-824 |
| ISSN: | 1525-0016 |
| DOI: | 10.1038/mt.2008.26 |
| Popis: | This article is available open access through the publisher’s website at the link below. Copyright © 2008 The American Society of Gene Therapy. Due to its early onset and severe prognosis, cystic fibrosis (CF) has been suggested as a candidate disease for in utero gene therapy. In 1997, a study was published claiming that to how transient prenatal expression of CF transmembrane conductance regulator (CFTR) from an in utero –injected adenovirus vector could achieve permanent reversal of the CF intestinal pathology in adult CF knockout mice, despite the loss of CFTR transgene expression by birth. This would imply that the underlying cause of CF is a prenatal defect for which lifelong cure can be achieved by transient prenatal expression of CFTR. Despite criticism at the time of publication, no independent verification of this contentious finding has been published so far. This is vital for the development of future therapeutic strategies as it may determine whether CF gene therapy should be performed prenatally or postnatally. We therefore reinvestigated this finding with an identical adenoviral vector and a knockout CF mouse line (CftrtmlCam) with a completely inbred genetic background to eliminate any effects due to genetic variation. After delivery of the CFTR-expressing adenovirus to the fetal mouse, both vector DNA and transgenic CFTR expression were detected in treated animals postpartum but statistically no significant difference in survival was observed between the Cftr–/– mice treated with the CFTR-adenovirus and those treated with the control vector. Sport Aiding Medical Research for Kids, the Cystic Fibrosis Trust, and the Katharine Dormandy Trust. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|